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ABSTRACT 
Zika virus (ZIKV) clinical presentation and frequency/duration of shedding 
need further clarification. Symptomatic ZIKV-infected individuals identified 
in two hospitals in Sao Paulo State, Brazil, were investigated regarding clinical 
characteristics, shedding in body fluids, and serodynamics. Ninety-four of 235 
symptomatic patients (Site A: 58%; Site B: 16%) had Real-Time PCR-confirmed 
ZIKV infection; fever, headache and gastrointestinal symptoms were less frequent, 
and rash was more frequent compared to ZIKV-negative patients. Real-Time PCR 
in serum had worse performance compared to plasma, while urine had the highest 
sensitivity. Shedding in genital fluids and saliva was rare. IgM positivity was the 
highest <14 days after the symptoms onset (86%), decreasing >28 days (24%); 
IgG positivity increased >14 days (96%) remaining positive in 94% of patients 
>28 days. ZIKV prevalence varied importantly in two neighboring cities during 
the same transmission season. Urine Real-Time PCR can improve diagnostic 
sensitivity; serum testing is less useful. Accurate serological tests are needed to 
improve diagnosis and surveillance.
KEYWORDS: Zika virus. Differential diagnosis. Kinetics. Body fluids. Polymerase chain 
reaction. Real-Time Polymerase Chain Reaction. Serology. Brazil.
INTRODUCTION
In 2016, the World Health Organization (WHO) declared Zika virus (ZIKV) 
infection-related microcephaly and other neurological disorders a Public Health 
Emergency of international concern1. Since early 2015, the geographic spread 
of ZIKV has been reported to increase in Brazil, with the potential for broader 
dissemination due to the lack of pre-existing exposure of populations, absence 
of effective preventive methods and widespread distribution of the transmitting 
Aedes mosquito vector2-6. Many reports have also shown that the infection can 
be transmitted from person to person through sexual contact, which could further 
increase the potential for ZIKV spreading7-13. However, while some studies have 
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explored the frequency, further characterization of viral 
load and duration of viral shedding in urine, saliva and 
genital fluid of ZIKV-infected patients, could improve the 
understanding of potential transmission dynamics14,15. 
Infection with ZIKV is commonly asymptomatic or 
associated with mild febrile symptoms and pruritic skin 
eruption16. Rare neurologic complications of acute ZIKV 
infection in adults, such as the Guillain-Barre syndrome, 
myelitis and encephalitis have also been described17-19. 
Further characterization of ZIKV clinical case definition 
is still necessary in the context of co-circulating Dengue 
(DENV) and Chikungunya (CHIKV) infections, frequently 
observed in Central and South America.
Ribeirao Preto and Araraquara are medium-sized cities in 
the countryside of Sao Paulo State, Brazil, with an estimated 
population of 682,302 and 230,770 inhabitants respectively20. 
Both municipalities have documented an alarmingly high 
incidence of DENV in 2016, accumulating almost 60,000 
reported DENV cases21. During the same period, 1,376 ZIKV 
infections and 195 CHIKV infections were reported22,23. 
In this study, we identified individuals with ZIKV 
infection in a cohort of patients who sought medical care 
with acute arboviral symptoms in Araraquara and Ribeirao 
Preto in 2016. We described the clinical characteristics 
and results from the etiologic investigation at the time 
of enrollment, and prospective measurements of ZIKV 
serodynamics and ZIKV Real-Time polymerase chain 
reaction (RT-PCR) in blood, urine, saliva and genital fluid 
samples for participants with confirmed ZIKV infection. 
METHODS
Study population and settings
We enrolled consecutive patients aged 16 and older 
attending the emergency department at Serviço Especial 
de Saude in Araraquara, Brazil (Site A) and Sao Francisco 
Hospital in Ribeirao Preto, Brazil (Site B) between January 
and September 2016. Patients were considered eligible 
when presenting with acute (<14 days) symptoms including 
at least two of the following: fever (>37.8 oC axillary 
temperature), maculopapular rash, headache, myalgia, 
arthralgia, fatigue, bleeding or conjunctivitis. We excluded 
participants with febrile symptoms considered to be related 
to other infections. 
Study procedures
Eligible participants were interviewed for the assessment 
of demographic characteristics, current symptoms and 
medical comorbidities. Possible past DENV exposure 
was ascertained through self-reporting of participants. A 
peripheral blood sample was collected for ZIKV testing 
by RT-PCR for all participants. For participants allocated 
in Site B, baseline investigation also included DENV and 
CHIKV testing by RT-PCR. For participants allocated in 
Site A, ZIKV was also tested by RT-PCR in urine samples. 
Results were communicated to healthcare providers and 
participants. Participants with confirmed ZIKV underwent 
three additional visits (<14, 15-28 and >28 days following 
symptoms onset) during which trained nurses collected a 
blood sample, while urine, saliva and cervicovaginal fluid 
samples were self-collected. . Whole saliva samples were 
self-collected by spontaneous salivation. Cervicovaginal 
fluid was self-collected using a cotton swab. One nursing 
mother provided breast milk samples at 20 and 23 days 
after symptoms initiation. We were also able to collect late 
cervicovaginal fluid samples using a brush (Evalyn Brush 
– Rovers Medical Devices BV, Oss, The Netherlands) one 
year after the baseline for ZIKV RT-PCR. Semen samples 
were obtained by masturbation from six participants, one 
year after the baseline, with complete analysis reported in 
a separated manuscript24. 
Laboratory methods
All samples were maintained under refrigeration 
(4-8 oC) up to 72 h until delivery in a local laboratory. 
The genital swab was plunged in 500 µL of DNAse free 
water and slowly homogenized for 30 s. Then, they were 
immediately stored in aliquots of 500 µLat -80 ºC until 
analysis. Nucleic acid extraction was performed using 
EasyMag automated system (bioMérieux®, Paris, France) 
according to the manufacturer’s instructions. The one-step 
multiplex RT-PCR assay for CHIKV/DENV1-4 and ZIKV 
was performed according to the protocols and primer sets 
described previously25-28 using the TaqMan® Fast Virus 
1-Step Master Mix (Life Technologies®, Austin, USA). 
Detection of anti-ZIKV IgM and IgG was performed 
by a commercial ELISA kit (Anti-Zika Virus ELISA, 
EUROIMMUN, Lübeck, Germany)29, according to the 
manufacturer’s instructions.
Statistical analysis
Baseline characteristics and the presence of each 
symptom at the time of enrollment and follow-up visits 
were described by using counts, proportions, medians and 
interquartile ranges (IQR), as appropriate. We used the 
Wilcoxon rank-sum test, the Chi-square or the Fisher’s exact 
test for comparisons between ZIKV-positive and -negative 
groups (categorical variables) and the Student’s t-test 
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for continuous quantitative variables. All analyses were 
performed by the Stata software, version 13.1 (StataCorp. 
College Station, TX: StataCorp LP). 
Ethical aspects
The institutional Ethics and Research Committee of the 
University of Sao Paulo Medical School, as well as local 
ethical committees, approved the study protocol (Process 
Nº 1.489.145/2016 and 25706913.6.0000.0066/2014). All 
participants signed an informed consent form. 
RESULTS
A total of 235 patients with a median age of 41 years 
(IQR, 31-54) were enrolled. Women comprised 69% of 
the sample, 24 (11%) of whom were pregnant, 23% of 
participants had at least one chronic comorbidity and 
31% reported prior DENV infection (Table 1). Etiologic 
investigation of the arboviral syndrome at the time 
of admission included ZIKV testing only for the 134 
participants of Site A, and ZIKV, DENV and CHIKV 
testing for the 101 participants of Site B. Overall, 94 
participants (40%) had confirmed ZIKV infection by 
RT-PCR in either plasma, serum or urine samples, 58% 
(95%CI: 49-67%) in Site A and 16% (95%CI: 9-24) in 
Site B. In addition, in site B, prevalence of RT-PCR-
positive DENV was 10%, while CHIKV or coinfections 
were not detected. ZIKV-positive patients were slightly 
older (44 versus 38 years, p=0.001) and included a higher 
(although not statistically significant) proportion of female 
participants compared with the ZIKV-negative group (76 
versus 64%, p=0.058). At the time of enrollment, the 
median time since symptoms onset was 3 days (IQR, 
1-4) for ZIKV-positive participants and 4 days (IQR, 
2-5) for ZIKV-negative participants (p<0.001). Clinical 
presentation was broadly similar for ZIKV-positive 
and ZIKV-negative patients, although ZIKV-positive 
patients reported significantly more episodes of fever, 
headache, cutaneous rash, while gastrointestinal symptoms 
(abdominal pain, nausea, vomiting, and diarrhea) were less 
frequent, compared to ZIKV-negative patients. 
Table 1 - Demographic and clinical characteristics of the study participants according to Zika virus RT-PCR results at the time of 
enrollment.
Patient characteristics All participants N=235
Zika-positive 
N=94 (40%)
Zika-negative 
N=141 (60%) p-value
Age 41 (31-54) 44 (36-59) 38 (29-52) 0.001
Female sex (%) 161/235 (69) 71/94 (76) 90/141 (64) 0.058
Pregnant (%) 18/159 (11) 7/70 (10) 11/89 (12) 0.641
Chronic comorbidities (%) 53/226 (23) 24/86 (28) 29/140 (21) 0.215
Prior dengue infection (%) 70/229 (31) 29/92 (32) 41/137 (30) 0.797
Symptoms at enrollment
Days with symptoms 4 (2-5) 3 (1-4) 4 (2-5) <0.001
Fever (%) 121/232 (52) 40/92 (43) 81/140 (58) 0.032
Rash (%) 201/235 (86) 89/94 (95) 112/141 (79) 0.001
Pruritus (%) 145/213 (68) 61/93 (66) 84/120 (70) 0.494
Petechiae (%) 12/131 (9) 8/75 (11) 4/56 (7) 0.555
Bleeding symptoms (%) 11/100 (11) 4/16 (25) 7/84 (8) 0.073
Conjunctivitis (%) 25/231 (11) 9/91 (10) 16/140 (11) 0.713
Arthralgia (%) 152/234 (65) 62/94 (66) 90/140 (64) 0.793
Articular edema (%) 35/134 (26) 25/78 (32) 10/56 (18) 0.065
Headache (%) 157/234 (67) 56/94 (60) 101/140 (72) 0.045
Weakness (%) 27/134 (20) 16/78 (21) 11/56 (20) 0.901
Myalgia (%) 69/129 (53) 40/75 (53) 29/54 (54) 0.967
Sore throat/cough (%) 42/129 (33) 27/75 (36) 15/54 (28) 0.326
Gastrointestinal symptoms* (%) 87/164 (53) 33/80 (41) 54/84 (64) 0.003
Continuous variables are presented as medians and interquartile ranges. RT-PCR: real-time polymerase chain reaction. *Abdominal 
pain, nauseas, vomit, diarrhea
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Given the uncertainties on the ideal specimen for 
ZIKV diagnostic testing at the time this study was 
carried out, samples collected for testing at the time of 
enrollment included plasma, serum and urine samples in 
different combinations as described in Figure 1. Among 
participants who had a positive ZIKV RT-PCR in at least 
one of the specimens tested, RT-PCR was negative in 
31% (24/78, 95% CI: 21-42%) of plasma samples, 46% 
(12/26, 95% CI: 27-67%) of serum samples, and 5% (4/78, 
95% CI: 0-13%) of urine samples. 
ZIKV-positive participants were followed-up during 
three additional visits with medians of 13 (IQR, 11-14), 
17 (IQR, 16-20) and 47 (IQR, 31-52) days after symptoms 
onset. Patients were invited to provide additional blood, 
urine, genital fluids, saliva and breast milk (if breastfeeding) 
samples for ZIKV RT-PCR. ZIKV was detected at follow-
up visits 1 and 2 more frequently in urine than in plasma 
and serum samples (Table 2). On visit 3, ZIKV was still 
detectable in plasma samples of two patients (11%), in 
serum of one patient (50%) and in urine samples of three 
patients (19%). 
Ten women were tested at least once for ZIKV in genital 
fluids, with only one woman having a positive RT-PCR 
result. She was a 26-year-old non-pregnant participant who 
was enrolled three days after the onset of rash, headache 
and arthralgia, and had a cervicovaginal sample collected 
18 days after the initial symptoms. The vaginal fluid was her 
only ZIKV positive sample besides a plasma sample. There 
were no data available on her sexual partner’s symptoms 
or infection status. Besides, genital fluid samples were 
collected from 16 women with confirmed ZIKV infection 
with a median of 12 months (IQR, 11-14) after enrollment 
and none tested positive for ZIKV RT-PCR (data not shown).
As shown in Table 2, saliva was tested in a small 
number of patients across two follow-up visits with no viral 
detection. One nursing mother who had ZIKV symptoms 
onset at week 36 of gestation provided breast milk samples 
20, 23 and 30 days after symptoms onset. The sample 
Figure 1 - Investigation of arboviral diseases at enrollment.
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collected 20 days after symptoms onset tested positive for 
ZIKV RT-PCR, as well as in Vero cells culture. We tested 
cord blood, saliva and urine samples from the infant at 
birth, and re-tested another urine sample one month after 
birth: all infant samples were negative for ZIKV RT-PCR. 
Unfortunately, blood samples from this infant were not 
tested by ZIKV serology.
ZIKV serology results at the time of enrollment and 
follow-up visits are presented in Table 3. At the time of 
enrollment, four out of 72 participants with RT-PCR-
positive ZIKV infection (6%) had positive ZIKV IgM and 
11 (15%) had positive ZIKV IgG results; two (3%) were 
positive for both IgM and IgG. Among 85 participants with 
negative baseline ZIKV RT-PCR, five (6%) had positive 
ZIKV IgM, 21 (25%) had positive ZIKV IgG and one 
(1%) was positive for both, IgM and IgG. Serology was 
performed in subsequent visits only for participants with 
positive baseline ZIKV RT-PCR. On visit 1, only seven 
participants were tested and six (86%) had positive results 
for both, IgM and IgG. On visit 2, 65% of participants had 
positive IgM and 96% had positive IgG, while on visit 3, 
only 4 (24%) of those tested remained IgM positive and 
94% were IgG positive. On follow-up visits, most patients 
with positive IgM were also positive for IgG.
Pregnancy outcomes for ZIKV-positive pregnant 
participants were known for six out of seven cases. One 
participant with first-trimester pregnancy had a miscarriage 
at gestational week seven, 22 days after the enrollment 
and 26 days after symptoms onset. She was hospitalized 
for curettage and discharged without additional medical 
complications. No investigation was performed on the fetus 
or on miscarriage products. Four participants with third-
trimester pregnancies and one participant with a second-
trimester pregnancy at the time of acute ZIKV infection 
gave birth to children without apparent signs of Congenital 
Zika Syndrome according to the initial evaluation. Eighteen 
to 21 months after birth, all five children were still under 
neuropediatric follow-up and had no signs or symptoms of 
neurological or developmental abnormalities.
DISCUSSION
In this hospital-based study, we enrolled 235 patients 
from two cities in the Sao Paulo State, Brazil, for whom 
Table 3 - Zika virus serology among 94 patients with confirmed Zika virus infection and among 85 patients with negative Zika virus 
RT-PCR at the time of enrollment.
Visit Median days since 
symptoms onset (IQR) Positive IgM (%) Positive IgG (%) IgM/IgG dual positive (%)
Patients with confirmed Zika virus infection (N=94)
Baseline 3 (1-4) 4/72 (6) 11/72 (15) 2/72 (3)
Visit 1 (≤14d) 13 (11-14) 6/7 (86) 6/7 (86) 6/7 (86)
Visit 2 (15-28d) 17 (16-20) 32/49 (65) 47/49 (96) 30/49 (61)
Visit 3 (>28d) 47 (31-52) 4/17 (24) 16/17 (94) 4/17 (24)
Patients with negative Zika virus RT-PCR at enrollment (N=85)
Baseline 4 (2-5) 5/85 (6) 21/85 (25) 1/85 (1)
IQR: interquartile range; RT-PCR: real-time polymerase chain reaction
Table 2 - Zika virus RT-PCR detection in body fluids during follow-up of 94 patients with confirmed Zika virus infection at the time 
of enrollment.
Visit
Median 
days since 
symptoms 
onset (IQR)
Zika virus in 
plasma (%)
Zika virus in 
serum (%)
Zika virus in 
urine (%)
Zika virus in 
genital fluids 
(%)
Zika virus in 
saliva (%)
Zika virus in 
breast milk (%)
Baseline 3 (1-4) 70/94 (74) 14/26 (54) 74/78 (95) - - -
Visit 1 (≤14d) 13 (11-14) 2/20 (10) 0/9 (0) 12/18 (67) - - -
Visit 2 (15-28d) 17 (16-20) 3/53 (6) 2/4 (50) 13/42 (31) 1/5* (20) 0/6 (0) 1/1& (100)
Visit 3 (>28d) 47 (31-52) 2/18 (11) 1/2 (50) 3/16 (19) 0/10 (0) 0/12 (0) 0/1 (0)
IQR: interquartile range; RT-PCR: real-time polymerase chain reaction; *ZIKV positive in vaginal swab 28 days after symptoms 
onset; &ZIKV positive in breast milk 20 days after symptoms onset
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investigation of acute ZIKV infection was performed by 
blood or urine RT-PCR. We found an overall prevalence 
of 40% of ZIKV-positive patients, who presented with 
cutaneous rash, fever, headache and less frequently with 
gastrointestinal symptoms when compared to ZIKV-
negative patients. Few patients had detectable ZIKV RNA 
in plasma samples (n=2 or 11%), serum (n=1 or 50%) and 
urine (n=3 or 19%) up to the last follow-up visit >28 days 
after enrollment. We reported the presence of ZIKV in 
genital fluids of one female patient. We have also observed 
the presence of ZIKV in breast milk, and, although we 
were able to isolate ZIKV in culture, we cannot confirm 
the potential viral transmission of breast milk.
These findings corroborate those of more detailed viral 
kinetics studies performed in Puerto Rico after the follow-
up of 150 RT-PCR-confirmed ZIKV infection patients from 
whom serum, urine, saliva, semen and vaginal secretion 
specimens were analyzed until all specimens became 
RT-PCR negative. They were able to determine the median 
time of viral shedding, which was highest for semen samples 
(34 days), followed by serum (14 days) and urine (8 days) 
samples. Interestingly, only one among 50 women tested 
positive in vaginal fluid15. Persistence of ZIKV in genital 
fluids has also been described in a smaller study conducted 
in Spain, which identified RT-PCR-positive samples in 
one of four women and one of five tested men, with viral 
shedding detected between days 37 and 69 for vaginal fluids 
and between days 23 and 107 for semen30.
Although Araraquara (Site A) and Ribeirao Preto (Site B) 
are only 70 km apart and enrollment in both cities took place 
in the same year, ZIKV prevalence was strikingly different, 
of 58% and 16%, respectively. Our findings and conclusions 
are also quite similar to those of a study conducted in another 
part of the Sao Paulo State31 and this disparity between 
ZIKV prevalences highlights the potential impact of different 
investigation protocols on results. Furthermore, it is essential 
to understand the local ZIKV epidemiology based not only 
on clinical definitions, which may be less useful in settings 
with lower epidemic intensity, but also on laboratory-based 
surveillance of standardized samples and time points. In 
2016, 236 and 1,140 ZIKV cases were reported in Site A 
and Site B, respectively, corresponding to an incidence 
rate of 102.3 and 167.1/100,000 inhabitants, respectively22. 
However, it is likely that data presented in official reports 
are an underestimate of the actual incidence given the 
low availability of diagnostic tools and the frequency of 
asymptomatic infections. 
ZIKV can be identified by RT-PCR from different 
body fluids and the best specimens for diagnosis are still 
to be defined. Our results suggest that RT-PCR testing in 
urine is more sensitive than in plasma, while serum was 
the specimen less likely to be positive. ZIKV RT-PCR 
testing in whole blood, has shown to be the most frequently 
positive fluid in a study conducted in Guadeloupe32, but was 
unfortunately not tested in our study. Among ten women 
tested for ZIKV detection in genital fluids on visits 2 or 
3, only one was positive 18 days after symptoms onset, 
which is slightly longer frametime than the ones previously 
reported33-35. Among 16 women tested 12 months after the 
initial infection, none had detectable ZIKV suggesting 
that ZIKV detection in female genital fluids is probably 
rare and short-lived, but this has not been systematically 
characterized hitherto33,34. In addition, probable ZIKV 
female-to-male sexual transmission has also been 
reported36. The quantification of ZIKV transmission risk 
through sexual intercourse is still to be determined, and this 
would represent important information to characterize the 
potential trajectory of the ZIKV epidemic37.
Serological dynamics of ZIKV infection were analyzed 
in the 94 patients with confirmed ZIKV infection. We 
observed that 6% of patients were IgM positive and 
15% were IgG positive at the time of enrollment, a 
median of 3 days after symptoms onset; as expected, 
IgM positivity increased between 14 and 28 days and 
decreased sharply after that, while IgG positivity increased 
around 14 days and remained positive in the majority 
of tested patients. Interestingly, among 85 patients with 
negative ZIKV RT-PCR at the baseline who underwent 
serology, 27 (32%) were positive for IgM, IgG or both. 
We were not able to discriminate whether these were true 
ZIKV infections with negative RT-PCR or false positive 
serological results. Although our study was not explicitly 
designed to address the performance of current serological 
tests, our results corroborate the findings from other studies 
that suggested a lower sensitivity of the Euroimmune IgM 
compared to IgG38-40 antibodies detection
Our study had some limitations. Because this study was 
conducted in the context of real-life routine clinical settings, 
we had missing observations and heterogeneous testing of 
specimens in different time points. Data on prior DENV 
infection was self-reported by participants, a procedure that 
is more prone to patients’ memory bias. It is possible that 
patients with no previously reported DENV had been exposed 
to the virus with asymptomatic or mild disease presentation. 
Unfortunately, it was not possible to perform DENV serology. 
This information would have been useful in the interpretation 
of ZIKV serological dynamics, as has been highlighted by our 
group and others41. Information on yellow fever vaccination 
was not collected from study participants and could also 
have potentially influenced ZIKV serology interpretation. 
Moreover, potential subjectivity in the identification of 
eligible participants by excluding those with other suspected 
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infections based on clinical evaluation could have impacted 
our findings. Despite these limitations, our study provides 
useful information on some of the viral and serological 
kinetics of ZIKV in the context of an epidemic. 
In conclusion, our study found critical differences in 
ZIKV prevalence among symptomatic patients presenting 
with similar arboviral syndromes in two neighboring cities 
in the Sao Paulo State, Brazil. In addition to a heterogeneous 
occurrence, nonspecific symptoms and overlapping clinical 
definitions for ZIKV, DENV, and CHIKV infections, 
highlights the need for accurate and accessible diagnostic 
tests, that should be timely performed using the specimens 
more likely to be positive. Our findings confirm the results 
from previous studies showing that urine ZIKV RT-PCR 
testing in the acute phase of infection can improve the 
sensitivity of diagnosis, while testing serum is probably less 
useful despite more sustained shedding in some cases. Higher 
sensitivity and specificity serological tests are needed for the 
diagnosis of patients who seek medical attention after the 
period of ZIKV detection by RT-PCR and for surveillance 
purposes in settings of high DENV background infection.
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